Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Adaptimmune Therapeutics in a research report issued on Tuesday, March 25th. Leerink Partnrs analyst J. Chang forecasts that the biotechnology company will earn ($0.10) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics' current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The company had revenue of $3.22 million for the quarter, compared to analysts' expectations of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.
Other research analysts have also recently issued reports about the company. Scotiabank decreased their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Saturday. They set a "buy" rating on the stock. HC Wainwright dropped their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday. Wells Fargo & Company reduced their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating on the stock in a research report on Friday, March 21st. Finally, Guggenheim lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research note on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1.83.
View Our Latest Stock Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Trading Up 18.3 %
Shares of NASDAQ:ADAP traded up $0.04 during mid-day trading on Friday, reaching $0.23. 4,217,385 shares of the company were exchanged, compared to its average volume of 1,735,626. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.55. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm's 50-day simple moving average is $0.50 and its 200 day simple moving average is $0.66. The firm has a market cap of $59.62 million, a price-to-earnings ratio of -1.06 and a beta of 2.52.
Hedge Funds Weigh In On Adaptimmune Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its holdings in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after acquiring an additional 98,581 shares in the last quarter. Virtu Financial LLC increased its position in shares of Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 21,769 shares during the last quarter. FMR LLC raised its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares in the last quarter. Finally, Two Seas Capital LP purchased a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth $7,992,000. Hedge funds and other institutional investors own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
